share_log

ペルセウス---大幅反発、PPMX-T003の真性多血症(PV)患者による第I相試験が終了

Perseus - Significant rebound, Phase I clinical trial of PPMX-T003 for true polycythemia vera (PV) patients has been completed.

Fisco Japan ·  Jun 30 21:33


Marked rebound. After the end of trading on the 28th, it was announced that the phase I trial of the developing anti-transferrin receptor 1 (TfR1) antibody "PPMX-T003" for patients with true polycythemia vera (PV) has ended. At the request of the sixth and last patient, the trial was terminated and the study was completed after the required observations. No reports of serious adverse events that could jeopardize safety have been made, and there are no changes to this year's performance or the derived plan until the end of March 2025.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment